SCPS vs. EVLO, ONCSQ, AEHAW, GRFS, LLY, NVO, JNJ, MRK, ABBV, and AZN
Should you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Evelo Biosciences (EVLO), OncoSec Medical (ONCSQ), Aesther Healthcare Acquisition (AEHAW), Grifols (GRFS), Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), and AstraZeneca (AZN).
Evelo Biosciences (NASDAQ:EVLO) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
Evelo Biosciences has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.
In the previous week, Evelo Biosciences had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Evelo Biosciences and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.64 beat Evelo Biosciences' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.
0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Evelo Biosciences received 168 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
Summary
Evelo Biosciences beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.
Get Scopus BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scopus BioPharma Competitors List
Related Companies and Tools
